The new ophthalmic formulation of bilastine: current state of knowledge
DOI:
https://doi.org/10.12775/QS.2026.49.67627Keywords
bilastine, ophthalmic, conjunctivitis, eye drops, ophthalmic solutionAbstract
Background: Allergic conjunctivitis is a common ocular condition characterized by itching, redness and tearing, which significantly affect patient comfort and daily functioning. Recently, a preservative-free ophthalmic formulation designed for once-daily administration has been developed, containing the second-generation antihistamine bilastine at a concentration of 0.6%.
Aim: The aim of this review was to summarize the current state of knowledge on the new ophthalmic formulation of bilastine, evaluate the available clinical evidence on its efficacy and safety and identify major research gaps and directions for future investigation.
Materials and methods: A literature review was performed using PubMed, Google Scholar, ResearchGate, Embase, Scopus and Web of Science, applying the keywords: bilastine, ophthalmic, ocular, eye, conjunctivitis, eye drops, ophthalmic solution and formulation.
Results: Phase II and phase III studies demonstrated a rapid onset of action and sustained symptom control for up to 16 hours following single-dose administration. Bilastine was shown to be noninferior to ketotifen in relieving ocular pruritus. An 8-week placebo-controlled study confirmed clinically meaningful improvements in patient-reported symptoms, a favorable safety profile and good tolerability. Experimental pharmacokinetic studies demonstrated high concentrations in the conjunctival tissue with minimal systemic exposure, supporting a once-daily dosing regimen.
Conclusions: The 0.6% ophthalmic bilastine formulation represents an effective and well-tolerated treatment option for allergic conjunctivitis, offering the advantages of rapid onset of action, prolonged efficacy lasting up to 16 hours and a preservative-free formulation. However, scientific data remain limited regarding the safety of long-term use beyond 8 weeks, its use in pediatric populations and direct comparative studies with other commercially available ophthalmic second-generation antihistamines.
References
1. Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67(11):1327–37. https://doi.org/10.1111/all.12009
2. Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: Diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020 Feb 1;124(2):118–34. https://doi.org/10.1016/j.anai.2019.11.014
3. Rodrigues J, Kuruvilla ME, Vanijcharoenkarn K, Patel N, Hom MM, Wallace DV. The spectrum of allergic ocular diseases. Ann Allergy Asthma Immunol. 2021 Mar 1;126(3):240–54. https://doi.org/10.1016/j.anai.2020.11.016
4. Church MK, Maurer M, Simons FER, Bindslev-Jensen C, Van Cauwenberge P, Bousquet J, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010 Apr;65(4):459–66. https://doi.org/10.1111/j.1398-9995.2009.02325.x
5. Bielory L, Lien KW, Bigelsen S. Efficacy and Tolerability of Newer Antihistamines in the Treatment of Allergic Conjunctivitis. Drugs. 2005 Feb 1;65(2):215–28. https://doi.org/10.2165/00003495-200565020-00004
6. Carter NJ. Bilastine: in allergic rhinitis and urticaria. Drugs. 2012 June 18;72(9):1257–69. https://doi.org/10.2165/11209310-000000000-00000
7. Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020 Mar;36(3):445–54. https://doi.org/10.1080/03007995.2019.1681134
8. Leonardi A, Quintieri L, Presa IJ, LLoves JM, Montero J, Benítez-Del-Castillo JM, et al. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. Curr Allergy Asthma Rep. 2024 July;24(7):347–60. https://doi.org/10.1007/s11882-024-01150-0
9. Suárez-Cortés T, Gonzalo A, Arana E, Guillén V, Andollo N. Ophthalmic Formulations for the Treatment of Allergic Conjunctivitis and Their Effect on the Ocular Surface: A Review of Safety and Tolerability Assessments in Clinical Trials. J Clin Med. 2024 Nov 16;13(22):6903. https://doi.org/10.3390/jcm13226903
10. Torrens I, Ganza Á, Hernández G, Gonzalo A, Zazpe A. Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2022 Nov;38(9):617–25. https://doi.org/10.1089/jop.2022.0024
11. Ochoa D, Román M, Belmonte C, Martín-Vilchez S, Mejía-Abril G, Abad-Santos F, et al. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. Adv Ther. 2021 July;38(7):4070–81. https://doi.org/10.1007/s12325-021-01801-y
12. Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study. J Investig Allergol Clin Immunol. 2023 July 27;33(4):271–80. https://doi.org/10.18176/jiaci.0800
13. Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis. J Investig Allergol Clin Immunol. 2024 June 17;34(3):167–76. https://doi.org/10.18176/jiaci.0894
14. Gomes PJ, Ciolino JB, Arranz P, Gonzalo A, Fernández N, Hernández G. Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials. J Investig Allergol Clin Immunol. 2024 Dec 3;34(6):385–94. https://doi.org/10.18176/jiaci.0940
15. Kuna P, Jutel M, Pulka G, Tokarski S, Arranz P, Hernández G, et al. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study. Clin Ophthalmol Auckl NZ. 2023;17:735–46. https://doi.org/10.2147/OPTH.S398168
16. Arana E, Gonzalo A, Andollo N, Goñi-de-Cerio F, Gómez-Fernández P, Salado C, et al. The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study. Sci Rep. 2024 Apr 26;14(1):9598. https://doi.org/10.1038/s41598-024-59190-5
17. Arana E, Gonzalo A, Andollo N, Pérez-Garrastachu M, Otero-Espinar F, Díaz-Tomé V, et al. The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study. Sci Rep. 2025 Mar 7;15(1):7987. https://doi.org/10.1038/s41598-025-91743-0
18. Ibrahim AG, Thomas LM. Formulation and Evaluation of Bilastine Thermosensitive Mucoadhesive Ophthalmic in situ Gel. Al-Rafidain J Med Sci ISSN 2789-3219. 2024 July 2;7(1):1–7. https://doi.org/10.54133/ajms.v7i1.1014
19. Rodríguez M, Vozmediano V, García-Bea A, Novák Z, Yáñez A, Campo C, et al. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria. Eur J Pediatr. 2020 May 1;179(5):801–5. https://doi.org/10.1007/s00431-019-03559-6
20. Majorek-Olechowska B, Slomskis T, Zollerová L, Martín I, Sánchez C, Gilaberte I, et al. Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. J Investig Allergol Clin Immunol. 2025 July 29;35(4):267–75. https://doi.org/10.18176/jiaci.1003
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jan Łozowski, Milena Mordarska, Alicja Piwowarczyk, Joanna Paluchowska, Natalia Gołąbek, Alicja Kodura, Przemysław Piątek, Julia Białas, Łukasz Szymański, Artur Merc
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 34
Number of citations: 0
